J Neurol Surg B Skull Base 2025; 86(S 01): S1-S576
DOI: 10.1055/s-0045-1803084
Presentation Abstracts
Podium Presentations
Oral Presentations

Vancomycin Powder Did Not Reduce Incidence of Surgical Site Infection (SSI) in a Cohort of 1,955 Cranial Surgeries

Wesley Shoap
1   LSU Department of Neurosurgery, New Orleans, Louisiana, United States
,
Robert Osorio
2   Department of Neurosurgery, University of California San Francisco School of Medicine, San Francisco, California, United States
,
Armond Esmaili
3   University of California San Francisco School of Medicine, San Francisco, California, United States
,
Phil Theodosopulos
2   Department of Neurosurgery, University of California San Francisco School of Medicine, San Francisco, California, United States
,
Shawn Hervey-Jumper
2   Department of Neurosurgery, University of California San Francisco School of Medicine, San Francisco, California, United States
,
Ezequiel Goldschmidt
2   Department of Neurosurgery, University of California San Francisco School of Medicine, San Francisco, California, United States
› Institutsangaben
 
 

    Background: The use of prophylactic vancomycin powder following cranial procedures remains controversial. In recent years, two large population studies concluded that subgaleal vancomycin powder effectively reduces SSI. However, these studies used a pre/postintervention design, limiting the interpretation of results.

    Methods: A cohort of 1,955 consecutive patients who underwent cranial procedures from July 2021 to May 2024 was studied retrospectively. SSI incidence was compared in one group that received subgaleal vancomycin at closure versus another group that did not. Additional analysis of SSIs included cultured organisms, surgical pathology, smoking status, and reoperations.

    Results: There was no significant difference in SSI incidence between patients receiving vs. not receiving vancomycin (9/1,467 (0.6%) vs. 1/492 (0.2%), p = 0.467). Supratentorial craniotomy was the most common procedure in both, with a higher predominance in the vancomycin group (57 vs. 40%, p < 0.001). There were 10 SSIs in total. The most frequently isolated pathogens were skin flora (6/10) followed by gram-negative hospital-acquired infections (3/10) and the most common surgical pathologies were atypical meningiomas (3/10) and glioblastomas (2/10).

    Conclusion: In the largest study on this topic to date, we demonstrate that vancomycin powder was not effective in reducing SSI incidence when applied following cranial procedures in this patient cohort. Although our study may lack the power to assess small differences, this result is notable given that (1) the SSI rate in the nonvancomycin group is about 10% of that reported in the same population from the original publications, and (2) the nonvancomycin group had a nonsignificant lower incidence of SSI. Large-scale randomized prospective studies are needed to better understand its utility.

    Zoom Image
    Zoom Image

    #

    Die Autoren geben an, dass kein Interessenkonflikt besteht.

    Publikationsverlauf

    Artikel online veröffentlicht:
    07. Februar 2025

    © 2025. Thieme. All rights reserved.

    Georg Thieme Verlag KG
    Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

     
    Zoom Image
    Zoom Image